Journal Information
Vol. 115. Issue 2.
Pages T215-T217 (February 2024)
Share
Share
Download PDF
More article options
Vol. 115. Issue 2.
Pages T215-T217 (February 2024)
Case and Research Letter
Full text access
Nadolol for Infantile Hemangiomas Previously Treated with Propranolol
Uso de nadolol en el tratamiento de hemangiomas infantiles previamente tratados con propranolol
Visits
2745
M. Colmenero Sendraa,
Corresponding author
sendracolmenero@gmail.com

Corresponding author.
, J. del Boz Gonzálezb, J.M. Segura Palaciosa, I. Valladares Millána, M. Eguiluz Solanac, M. de Troya Martína
a Servicio de Dermatología, Hospital Costa del Sol, Marbella, Málaga, Spain
b Servicio de Dermatología, Hospital Carlos Haya, Málaga, Spain
c Unidad de Farmacia Hospitalaria, Hospital Costa del Sol, Marbella, Málaga, Spain
Related content
M. Colmenero Sendra, J. del Boz González, J.M. Segura Palacios, I. Valladares Millán, M. Eguiluz Solana, M. de Troya Martín
This item has received
Article information
Full Text
Bibliography
Download PDF
Statistics
Figures (1)
Tables (1)
Table 1. Demographic characteristics of the patients and therapy timeline.
Full Text
To the Director,

Beta-blockers (BB) have become the treatment of choice for infantile hemangiomas (IH).1 Among this class of drugs, propranolol has taken the lead, consolidating its efficacy and safety profile,2 and becoming the only beta-blocker approved for this indication.3 However, some patients exhibit limited therapeutic response or experience related adverse events, leading us to consider other beta-blockers as an alternative to propranolol.4

We reviewed patients with IH treated with oral nadolol at the Dermatology Unit of Hospital Universitario Costa del Sol, Málaga, Spain from 2010 through 2022. Nadolol was administered in an oral solution formulation prepared at the hospital pharmacy at a concentration of 10mg/mL. The initial dose was 1mg/kg/day, divided into 2 doses every 12hours, with an increased 1mg/kg/day every 10 days (with a maximum dose of 3mg/kg/day) depending on the patient's response and tolerability to the drug.

Response to treatment was assessed using a validated visual analog scale5 that measures thickness and size in millimeters (a 5mm reduction is equivalent to a 10% change on the scale) and skin coloration. Good (complete involution or remissions >80%), partial (remissions from 50% to 80%), and incomplete responses (remissions<50%) can be identified here.

A total of 7 patients received nadolol, 6 of whom were women. The patients’ demographic and hemangioma-related clinical characteristics are shown in table 1. In all cases, nadolol was prescribed after previous use of propranolol.

Table 1.

Demographic characteristics of the patients and therapy timeline.

Patient 
Sex  Woman  Woman  Woman  Man  Woman  Woman  Woman 
Incidences during pregnancy  None  None  None  None  Post-term infant  Pre-term infant  None 
Location  Lower lip  Nasal tip  Left lower eyelid  Left upper eyelid  Dorsal  Scapular  Lower lip 
Size (in mm)  10  10  30  80  50  15 
Type  Mixed focal  Superficial focal  Deep focal  Mixed focal  Deep focal  Mixed focal  Superficial focal 
Age when propranolol therapy started (in months)  5.5  1.5  2.5 
Course of propranolol therapy 3mg/kg/day (in months)  15  21  24  10  27  14 
Reason for withdrawing propranolol  Lack of response  Lack of response  Lack of response  Regrowth, discontinue  Regrowth, discontinue  Regrowth, discontinue  Regrowth, discontinue 
Time until regrowth (in months)        14 
No. of attempts       
Course of nadolol therapy 2.5mg/kg/day (months)  19  15  16 
Response to nadolol therapy  Incomplete  Incomplete  Good response  Good response  Good response  Partial  Good response 

The median age when treatment with propranolol started was 4 months (IQR, 2.5-5.5), with all patients reaching the maximum dose of 3mg/kg/day. The median duration of treatment was 15 months (IQR, 10-24). The reason for withdrawing propranolol was a lack of response in 3 patients and lesion regrowth after drug discontinuation on several occasions in the remaining 4. None of our patients discontinued propranolol due to adverse events such as sleep disturbances or hypoglycemia. The median age when treatment with nadolol started was 21 months (IQR, 16-36) at a dose of 2.5mg/kg/day (IQR, 2-3), and a median course of 8 months (IQR, 7-16). Regarding effectiveness, 4 patients had good responses; 1 patient had a partial response (fig. 1); and 2 patients, incomplete responses. The rate of response was 5 out of 7 patients. No patient had to discontinue nadolol therapy for any drug-related adverse events. The timeline of treatments, courses, and patient responses are shown in table 1.

Figure 1.

Examples of responses to nadolol treatment: A) Deep focal hemangioma on the left lower eyelid; age when nadolol treatment started: 24 months; age when nadolol treatment was withdrawn: 43 months. Good response. B) Dorsal focal deep hemangioma; age when nadolol treatment started: 40 months; age when nadolol treatment was withdrawn: 48 months. Good response. C) Superficial focal hemangioma on the lower lip; age when nadolol treatment started: 11 months; age when nadolol treatment was withdrawn: 27 months. Good response. D) Mixed focal scapular hemangioma; age when nadolol treatment started: 30 months, age when nadolol treatment was withdrawn: 45 months. Partial response.

(0.29MB).

In our series of 7 cases, the main reason for switching from propranolol to nadolol was the regrowth of the hemangioma after discontinuation after several attempts, a well-documented phenomenon in the medical literature reported in nearly 25% of the cases.6 Risk factors for regrowth include female gender, head and neck location, segmental character, deep components, and a <9-month course of beta-blockers.4 The lack of initial response to propranolol was reported in 3 patients, a number similar to the one reported. The cause of this inefficiency is still unknown. However, treatment should go on for >6 months to increase the rate of success.6 In our series, the mean course of treatment exceeded this recommendation by far (up to 15 months). None of the patients switched to nadolol due to propranolol-related adverse events.

Nadolol is a water-soluble beta-blocker with a half-life of 12 to 24hours. These pharmacokinetic properties theoretically give it certain advantages over propranolol when administered to young patients. Since nanodol does not penetrate the blood-brain barrier, it has with fewer adverse events on the central nervous system, and thus fewer sleep disturbances compared to propranolol. However, same as it happens with propranolol, it is a non-cardioselective BB, meaning that it can cause the same adverse events due to its beta 2 and beta 3 adrenergic activity, such as hypoglycemia and bronchospasm.7 Since the main pathway for drug excretion is the GI tract (up to 70%), the infant's bowel movements needs to be monitored, especially after a case reported in the medical literature of a patient who died from nadolol intoxication who was suffering from constipation.8 On the other hand, its half-life is twice that of propranolol, which is associated with more stable drug levels in blood.9 This is the main hypothesis that may explain why nadolol may have faster onsets of action and be more effective than propranolol. A recent double, prospective, non-inferiority clinical trial comparing the efficacy and safety profile of nadolol vs propranolol10 demonstrated that the former was 59% faster than the latter in achieving a 75% reduction in size, and 105% faster in achieving hemangioma disappearance, all without more adverse events being reported.

In conclusion, nadolol has proven to be an effective and safe drug with a favorable pharmacokinetic profile, and non-inferior and faster rates of response compared to propranolol. This has turned it into the first-line therapy for the management of high-risk subtypes of hemangiomas with associated factors for recurrence.

Conflicts of interest

None declared.

References
[1]
C. Léauté-Labrèze, J.J. Voisard, N. Moore.
Oral Propranolol for Infantile Hemangioma.
N Engl J Med, 373 (2015), pp. 284-285
[2]
C. Léauté-Labrèze, P. Hoeger, J. Mazereeuw-Hautier, L. Guibaud, E. Baselga, G. Posiunas, et al.
A Randomized, Controlled Trial of Oral Propranolol in Infantile Hemangioma.
N Engl J Med, 372 (2015), pp. 735-746
[3]
Study to Demonstrate the Efficacy and Safety of Propranolol Oral Solution in Infants With Proliferating Infantile Hemangiomas Requiring Systemic Therapy - Full Text View - ClinicalTrials.gov [WWW Document] [accessed 19 Abr 2023]. Available from: https://www.clinicaltrials.gov/ct2/show/study/NCT01056341
[4]
S.D. Shah, E. Baselga, C. McCuaig, E. Pope, J. Coulie, L.M. Boon, et al.
Rebound Growth of Infantile Hemangiomas After Propranolol Therapy.
Pediatrics, 137 (2016), pp. e20151754
[5]
E. Pope, A. Chakkittakandiyil, I. Lara-Corrales, E. Maki, M. Weinstein.
Expanding the therapeutic repertoire of infantile haemangiomas: Cohort-blinded study of oral nadolol compared with propranolol.
Br J Dermatol, 168 (2013), pp. 222-224
[6]
C.K. Ahogo, K. Ezzedine, S. Prey, V. Colona, A. Diallo, F. Boralevi, et al.
Factors associated with the relapse of infantile haemangiomas in children treated with oral propranolol.
Br J Dermatol, 169 (2013), pp. 1252-1256
[7]
H. Yang, D.L. Hu, Q. Shu, X.D. Guo.
Efficacy and adverse effects of oral propranolol in infantile hemangioma: A meta-analysis of comparative studies.
World J Pediatr, 15 (2019), pp. 546-558
[8]
E. McGillis, T. Baumann, J. LeRoy.
Death associated with nadolol for infantile hemangioma: A case for improving safety.
Pediatrics, (2020), pp. 145
[9]
S. Kalsoom, A. Zamir, A.U. Rehman, W. Ashraf, I. Imran, H. Saeed, et al.
Clinical pharmacokinetics of nadolol: A systematic review.
J Clin Pharm Ther, 47 (2022), pp. 1506-1516
[10]
E. Pope, I. Lara-Corrales, C. Sibbald, C. Liy-Wong, N. Kanigsberg, B. Drolet, et al.
Noninferiority and Safety of Nadolol vs Propranolol in Infants with Infantile Hemangioma: A Randomized Clinical Trial.
JAMA Pediatr, 176 (2022), pp. 34-41
Copyright © 2023. AEDV
Download PDF
Idiomas
Actas Dermo-Sifiliográficas
Article options
Tools
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?